Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156363 | 0.89 | USP2 (0.56) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL1700547 | 0.86 | USP2 (0.53) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL1967958 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL18053621 | 0.81 | USP2 (0.59) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL8782075 | 0.81 | HPGD (0.51) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL30984754 | 0.80 | USP2 (0.50) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL1222835 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL22814520 | 0.78 | USP2 (0.47) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL1555865 | 0.78 | USP2 (0.59) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL4278413 | 0.77 | USP2 (0.54) | USP2SMN1; SMN2RECQLGPR119HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-0869955-B1 | N-ACYL-2-SUBSTITUTED-4-(BENZIMIDAZOLYL- OR IMIDAZOPYRIDINYL-SUBSTITUTED RESIDUES)-PIPERIDINES AS TACHYKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2001-10-24 | — | — | EP | disclosed |
| US-6110939-A | AS A SUBSTANCE P ANTAGONISTS TREATING TACHYKININ-MEDIATED DISEASE, ASTHMA, CENTRAL NERVOUS SYSTEM DISORDER | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-08-29 | — | — | US | disclosed |
| EP-0869955-A1 | N-ACYL-2-SUBSTITUTED-4-(BENZIMIDAZOLYL- OR IMIDAZOPYRIDINYL-SUBSTITUTED RESIDUES)-PIPERIDINES AS TACHYKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024350-A1 | N-ACYL-2-SUBSTITUTED-4-(BENZIMIDAZOLYL- OR IMIDAZOPYRIDINYL-SUBSTITUTED RESIDUES)-PIPERIDINES AS TACHYKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | USP2 4091/4885SMN1; SMN2 3052/4885RECQL 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.